PARADIGM-HF: Rationale and Design

Article Figures & Data

Figures

  • Figure 1.

    Study Design

    LCZ=LCZ696.Adapted from McMurray JJ et al. Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin-converting enzyme inhibition in patients with chronic systolic heart failure: rationale for and design of the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF). Eur J Heart Fail 2013;15(9):1062–1073.